INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $330,563 | -20.1% | 6,346 | -2.8% | 0.04% | -18.2% |
| Q2 2023 | $413,543 | +13.6% | 6,531 | -2.8% | 0.04% | +7.3% |
| Q1 2023 | $363,942 | +5.2% | 6,721 | +2.8% | 0.04% | -2.4% |
| Q4 2022 | $345,885 | -75.4% | 6,536 | -78.4% | 0.04% | -76.8% |
| Q3 2022 | $1,407,000 | -19.7% | 30,236 | -1.5% | 0.18% | -12.6% |
| Q2 2022 | $1,753,000 | +1.3% | 30,703 | -2.0% | 0.21% | +1.5% |
| Q1 2022 | $1,731,000 | +2.7% | 31,341 | -2.7% | 0.20% | +28.3% |
| Q4 2021 | $1,686,000 | +3.3% | 32,205 | -26.4% | 0.16% | -8.6% |
| Q3 2021 | $1,632,000 | -50.8% | 43,780 | -51.9% | 0.17% | -24.0% |
| Q2 2021 | $3,316,000 | +123.5% | 90,938 | +107.9% | 0.23% | +30.9% |
| Q1 2021 | $1,484,000 | +6.2% | 43,741 | -0.4% | 0.18% | -11.6% |
| Q4 2020 | $1,397,000 | – | 43,929 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |